| CAS NO: | 312636-16-1 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 25mg | 电议 |
| 100mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| Cas No. | 312636-16-1 |
| 别名 | 鞘氨醇激酶抑制剂 |
| 化学名 | 4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol |
| Canonical SMILES | C1=CC(=CC=C1C2=CSC(=N2)NC3=CC=C(C=C3)O)Cl |
| 分子式 | C15H11ClN2OS |
| 分子量 | 302.78 |
| 溶解度 | ≥ 15.15mg/mL in DMSO |
| 储存条件 | Store at -20° C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | SKI II is an inhibitor of sphingosine kinase with IC50 value of 0.5μM[1]. SKI II is selective against SK and has no inhibition of human protein kinases ERK2, PKC-I and the lipid kinase PI3K. It is reported that SKI II is not a competitive inhibitor at the ATP-binding site of SK. SKI II also inhibits endogenous SK in intact MDA-MB-231 cells [1]. As a SK inhibitor, SKI II prevents SK from catalyzing the generation of sphingosine 1-phosphate (S1P). The blockage of S1P formation leads to inhibition of proliferation, as well as the induction of apoptosis in cancer cells. SKI II shows cytotoxicity in T-24 human bladder carcinoma cells, MCF-7 human breast adenocarcinoma cells and the subline of MCF-7 cells, MCF-7/VP, with IC50 values of 4.6μM, 1.2μM and 0.9μM, respectively [1]. References: |
m.cnreagent.com